Drug Profile
Autologous corneal epithelial stem cell therapy - Chiesi/Holostem Terapie Avanzate
Alternative Names: GPLSCD-01; Holoclar; Limbal epithelial stem cell therapy - Chiesi/Holostem Terapie Avanzate; Living tissue equivalent - Chiesi/Holostem Terapie AvanzateLatest Information Update: 14 Jun 2018
Price :
$50
*
At a glance
- Originator Chiesi; Holostem Terapie Avanzate
- Class Eye disorder therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Limbal stem cell deficiency
Most Recent Events
- 12 Jun 2018 Launched for Limbal stem cell deficiency in Ireland and United Kingdom (Ophthalmic)
- 12 Jun 2018 Autologous corneal epithelial stem cell therapy - Chiesi/Holostem Terapie Avanzate receives Orphan Drug status for Limbal stem cell deficiency in USA
- 05 Sep 2017 Autologous corneal epithelial stem cell therapy is still registered for Limbal stem cell deficiency in European Union, Norway, Iceland and Liechtenstein (Opthalmic) (Chiesi pipeline, September 2017)